$PLBI - Proton Laboratories upmove by 28.6% at 0.0009 X 0.0012 +0.0002 on 560k shares. No news.

$PLBI - Proton Laboratories upmove by 28.6% at 0.0009 X 0.0012 +0.0002 on 560k shares. No news.

Price Alert Triggered for Implant Sciences Corp.
Implant Sciences Corp (IMSC) Price Changed +10.56% from Wednesday's Close.

IMSC increased +10.56% today and is currently trading at $1.02. This performance was better than its Electronic Equipment & Instruments industry peers as they fell 1.44%.

Please note you will receive only one "Price Changes 10% Since the Prior Day's Close" alert per day for Implant Sciences Corp.

$IMSC - Alert Triggered for Implant Sciences Corp.
Implant Sciences Corp (IMSC) Price Changed +10.56% from Wednesday's Close.

IMSC increased +10.56% today and is currently trading at $1.02. This performance was better than its Electronic Equipment & Instruments industry peers as they fell 1.44%.

Please note you will receive only one "Price Changes 10% Since the Prior Day's Close" alert per day for Implant Sciences Corp.

$IMSC - Alert Triggered for Implant Sciences Corp.
Implant Sciences Corp (IMSC) Price Changed +10.56% from Wednesday's Close.

IMSC increased +10.56% today and is currently trading at $1.02. This performance was better than its Electronic Equipment & Instruments industry peers as they fell 1.44%.

Please note you will receive only one "Price Changes 10% Since the Prior Day's Close" alert per day for Implant Sciences Corp.

$IMSC - Alert Triggered for Implant Sciences Corp.
Implant Sciences Corp (IMSC) Price Changed +10.56% from Wednesday's Close.

IMSC increased +10.56% today and is currently trading at $1.02. This performance was better than its Electronic Equipment & Instruments industry peers as they fell 1.44%.

Please note you will receive only one "Price Changes 10% Since the Prior Day's Close" alert per day for Implant Sciences Corp.

CLBI was up over 10% at one point this AM.

North Korean tensions seem to be favorably impacting homeland security issues today.

$CONX now 0.23 + 0.03 on 140k volume thus far.

$CONX now 0.23 + 0.03 on 140k volume thus far.

$CONX now 0.23 + 0.03 on 140k volume thus far.

Volume Alert Triggered for Corgenix Medical Corp.
CONX's Trading Volume Exceeded Daily Average by +405.62%

CONX is up $0.005 or 2.50% to $0.21 on heavy volume that exceeded its daily average by +405.62%. This performance is in-line-with the broader averages as the S&P 500 is up +0.58% on the day.

Please note you will receive only one "Trading Volume Exceeds Daily Average" alert per day for Corgenix Medical Corp.

$CONX - Corgenix Medical Volume Alert:

Alert Triggered for Corgenix Medical Corp.
CONX's Trading Volume Exceeded Daily Average by +405.62%

CONX is up $0.005 or 2.50% to $0.21 on heavy volume that exceeded its daily average by +405.62%. This performance is in-line-with the broader averages as the S&P 500 is up +0.58% on the day.

Please note you will receive only one "Trading Volume Exceeds Daily Average" alert per day for Corgenix Medical Corp.

$CONX - Corgenix Medical Volume Alert:

Alert Triggered for Corgenix Medical Corp.
CONX's Trading Volume Exceeded Daily Average by +405.62%

CONX is up $0.005 or 2.50% to $0.21 on heavy volume that exceeded its daily average by +405.62%. This performance is in-line-with the broader averages as the S&P 500 is up +0.58% on the day.

Please note you will receive only one "Trading Volume Exceeds Daily Average" alert per day for Corgenix Medical Corp.

$CONX - Corgenix Medical Volume Alert:

Alert Triggered for Corgenix Medical Corp.
CONX's Trading Volume Exceeded Daily Average by +405.62%

CONX is up $0.005 or 2.50% to $0.21 on heavy volume that exceeded its daily average by +405.62%. This performance is in-line-with the broader averages as the S&P 500 is up +0.58% on the day.

Please note you will receive only one "Trading Volume Exceeds Daily Average" alert per day for Corgenix Medical Corp.

$CONX - Corgenix Medical 0.20:

Atherotech Diagnostics Lab adds Corgenix AspirinWorks® Test for Aspirin Effect

AspirinWorks® Test measures levels of inflammatory chemical thromboxane, which can interfere with heart-protective effect of aspirin therapy

DENVER — April 2, 2013 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced that Atherotech Diagnostics Lab will carry its AspirinWorks® Test for determining aspirin effect.

Under terms of the agreement, Corgenix AspirinWorks product will be used to assess aspirin effect as part of Atherotech Diagnostic Lab’s cardiometabolic testing products. AspirinWorks is the only U.S. FDA-cleared test that measures the urinary biomarker 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect.

“Atherotech is one of the nation’s most recognized and respected labs for comprehensive cardiometabolic testing and cardiovascular risk assessment,” said Douglass Simpson, Corgenix’ President and Chief Executive Officer. “Atherotech’s access to the U.S. primary care market further strengthens the AspirinWorks product, a test that has proven its clinical utility by measuring aspirin effect, thereby enabling physicians to identify an additional influence on aspirin’s ability to aid in reducing heart attack and stroke risk.”

The AspirinWorks Test identifies those individuals who have elevated thromboxane levels despite taking a daily aspirin dose, with studies showing up to 25 percent of individuals not seeing the expected beneficial effects of aspirin. The thromboxane metabolite 11dhTxB2 identified by AspirinWorks has been clinically validated through extensive research and numerous well-designed and well-powered clinical trials. The AspirinWorks 11dhTxB2 Test is FDA-cleared and used by thousands of physicians to test and guide treatment for hundreds of thousands of patients each year worldwide.

Atherotech provides a full complement of more than 60 routine and specialty diagnostic tests, including its patented VAP® Lipid Panel, to help physicians establish the most effective course of treatment from a single source.

About the AspirinWorks Test

Launched in the U.S. in June 2007 following FDA 510(k) clearance, the AspirinWorks Test is available nationwide through major medical laboratories. Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office or patient service center, making the test convenient for both physician and patient. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com.



Company Contact:

Corgenix Medical Corp.
William Critchfield, Senior VP Operations and Finance and CFO
Phone (303) 453-8903
Email: wcritchfield@corgenix.com

Media Contact:

Armada Medical Marketing
Dan Snyders, Vice President,
Public Relations Supervisor
Phone: 303-623-1190 x 230
Email: dan@armadamedical.com

$CONX - Corgenix Medical 0.20:

Atherotech Diagnostics Lab adds Corgenix AspirinWorks® Test for Aspirin Effect

AspirinWorks® Test measures levels of inflammatory chemical thromboxane, which can interfere with heart-protective effect of aspirin therapy

DENVER — April 2, 2013 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced that Atherotech Diagnostics Lab will carry its AspirinWorks® Test for determining aspirin effect.

Under terms of the agreement, Corgenix AspirinWorks product will be used to assess aspirin effect as part of Atherotech Diagnostic Lab’s cardiometabolic testing products. AspirinWorks is the only U.S. FDA-cleared test that measures the urinary biomarker 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect.

“Atherotech is one of the nation’s most recognized and respected labs for comprehensive cardiometabolic testing and cardiovascular risk assessment,” said Douglass Simpson, Corgenix’ President and Chief Executive Officer. “Atherotech’s access to the U.S. primary care market further strengthens the AspirinWorks product, a test that has proven its clinical utility by measuring aspirin effect, thereby enabling physicians to identify an additional influence on aspirin’s ability to aid in reducing heart attack and stroke risk.”

The AspirinWorks Test identifies those individuals who have elevated thromboxane levels despite taking a daily aspirin dose, with studies showing up to 25 percent of individuals not seeing the expected beneficial effects of aspirin. The thromboxane metabolite 11dhTxB2 identified by AspirinWorks has been clinically validated through extensive research and numerous well-designed and well-powered clinical trials. The AspirinWorks 11dhTxB2 Test is FDA-cleared and used by thousands of physicians to test and guide treatment for hundreds of thousands of patients each year worldwide.

Atherotech provides a full complement of more than 60 routine and specialty diagnostic tests, including its patented VAP® Lipid Panel, to help physicians establish the most effective course of treatment from a single source.

About the AspirinWorks Test

Launched in the U.S. in June 2007 following FDA 510(k) clearance, the AspirinWorks Test is available nationwide through major medical laboratories. Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office or patient service center, making the test convenient for both physician and patient. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com.



Company Contact:

Corgenix Medical Corp.
William Critchfield, Senior VP Operations and Finance and CFO
Phone (303) 453-8903
Email: wcritchfield@corgenix.com

Media Contact:

Armada Medical Marketing
Dan Snyders, Vice President,
Public Relations Supervisor
Phone: 303-623-1190 x 230
Email: dan@armadamedical.com

$CONX - Corgenix Medical 0.20:

Atherotech Diagnostics Lab adds Corgenix AspirinWorks® Test for Aspirin Effect

AspirinWorks® Test measures levels of inflammatory chemical thromboxane, which can interfere with heart-protective effect of aspirin therapy

DENVER — April 2, 2013 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced that Atherotech Diagnostics Lab will carry its AspirinWorks® Test for determining aspirin effect.

Under terms of the agreement, Corgenix AspirinWorks product will be used to assess aspirin effect as part of Atherotech Diagnostic Lab’s cardiometabolic testing products. AspirinWorks is the only U.S. FDA-cleared test that measures the urinary biomarker 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect.

“Atherotech is one of the nation’s most recognized and respected labs for comprehensive cardiometabolic testing and cardiovascular risk assessment,” said Douglass Simpson, Corgenix’ President and Chief Executive Officer. “Atherotech’s access to the U.S. primary care market further strengthens the AspirinWorks product, a test that has proven its clinical utility by measuring aspirin effect, thereby enabling physicians to identify an additional influence on aspirin’s ability to aid in reducing heart attack and stroke risk.”

The AspirinWorks Test identifies those individuals who have elevated thromboxane levels despite taking a daily aspirin dose, with studies showing up to 25 percent of individuals not seeing the expected beneficial effects of aspirin. The thromboxane metabolite 11dhTxB2 identified by AspirinWorks has been clinically validated through extensive research and numerous well-designed and well-powered clinical trials. The AspirinWorks 11dhTxB2 Test is FDA-cleared and used by thousands of physicians to test and guide treatment for hundreds of thousands of patients each year worldwide.

Atherotech provides a full complement of more than 60 routine and specialty diagnostic tests, including its patented VAP® Lipid Panel, to help physicians establish the most effective course of treatment from a single source.

About the AspirinWorks Test

Launched in the U.S. in June 2007 following FDA 510(k) clearance, the AspirinWorks Test is available nationwide through major medical laboratories. Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office or patient service center, making the test convenient for both physician and patient. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com.



Company Contact:

Corgenix Medical Corp.
William Critchfield, Senior VP Operations and Finance and CFO
Phone (303) 453-8903
Email: wcritchfield@corgenix.com

Media Contact:

Armada Medical Marketing
Dan Snyders, Vice President,
Public Relations Supervisor
Phone: 303-623-1190 x 230
Email: dan@armadamedical.com

TSA Updating Qualified Product Lists for AT, ETD Screening Systems
HS Today
By: Mickey McCarter
04/01/2013 (9:00am)

The Transportation Security Administration (TSA) recently moved to update its qualified product lists for advanced technology (AT) passenger screening systems for carry-on baggage and for desktop and portable explosive trace detectors (ETDs).

In separate announcements this week, TSA called for white papers from vendors producing AT carry-on baggage screening and ETD screening equipment to update product lists first established in 2008.

Qualified AT systems should have a processing time of 25 seconds or less, TSA said in an announcement on March 25. The systems provide "automated threat detection capability that highlights explosives." The system must be relatively lightweight and fit into compact configurations offered by most passenger screening checkpoints.

For ETD systems, companies must specify if they are offering desktop or portable ETD. The qualified product list will contain separate information on both.

ETD systems must able to distinguish harmless substances from explosives, TSA said in an announcement. Companies must describe the equipment's alarm rate and how it processes a sample in a short timeframe. Desktop ETDs must process a sample in 10 seconds or less; portable ETDs, 20 seconds or less.

For all equipment, respondents must send TSA a five-page white paper on their product. The Transportation Security Laboratory at Atlantic City Airport, NJ, must receive two working units for evaluation. The lab will take two to four weeks to conduct qualification testing on the products.

If a product passes qualification testing, TSA then will run an operation test and evaluation on the product. Operational tests will occur at different airports over 30 to 60 days in addition to one week of training and adjustment time. During operational test and evaluation, companies must support and maintain a number of different units at no cost to the government.

Should the product enter operational test and evaluation, TSA will provide a company with a formal request for proposals.

TSA will analyze test and evaluation results to determine if a product is suitable for use. If a product passes all steps of the process for the qualified product list, TSA will add the qualified technology to the list. A contracting officer will inform the company involved that it is eligible to respond to a request for proposals. Proposals to include unit pricing help TSA determine whether to actually buy any devices. Qualification for the product list does not necessarily mean TSA will buy the products.

$IMSC - Implant Sciences wins African security contract:

http://m.yahoo.com/w/legobpengine/finance/news/implant-sciences-wins-contract-seven-110000580.html?.intl=us&.lang=en-us

$IMSC - Implant Sciences wins African security contract:

http://m.yahoo.com/w/legobpengine/finance/news/implant-sciences-wins-contract-seven-110000580.html?.intl=us&.lang=en-us

$IMSC - Implant Sciences wins African security contract:

http://m.yahoo.com/w/legobpengine/finance/news/implant-sciences-wins-contract-seven-110000580.html?.intl=us&.lang=en-us

$IMSC - Implant Sciences' Quantum Sniffers Play Growing Role in Corporate Security in Africa

WILMINGTON, MA -- (MARKETWIRE) -- 03/26/13 -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has sold its Quantum Sniffer™ QS-H150 handheld explosives trace detector to a customer in Africa for use in corporate security for a financial institution.

Some regions in Africa have experienced growing instability, with an increasing number of insurgencies and terrorist attacks, particularly on foreign interests. The response from security providers has been an increasing reliance on Quantum Sniffers to meet their security needs.

"Quantum Sniffers work consistently in difficult environments. In addition to the Quantum Sniffer's quality and consistent performance, customers in Africa are choosing our systems due its low-maintenance design and non-contact sampling, which enables a low total cost of ownership," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones.

"We continue to expand our market share in Africa through our expanded sales force, our growing distribution network, and our increasing reputation of being the latest standard in explosives trace detection," added Glenn D. Bolduc, Implant Sciences' President and CEO.

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector

The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor Contact:
Laurel Moody
646-810-0608
Email Contact

$IMSC - Implant Sciences' Quantum Sniffers Play Growing Role in Corporate Security in Africa

WILMINGTON, MA -- (MARKETWIRE) -- 03/26/13 -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has sold its Quantum Sniffer™ QS-H150 handheld explosives trace detector to a customer in Africa for use in corporate security for a financial institution.

Some regions in Africa have experienced growing instability, with an increasing number of insurgencies and terrorist attacks, particularly on foreign interests. The response from security providers has been an increasing reliance on Quantum Sniffers to meet their security needs.

"Quantum Sniffers work consistently in difficult environments. In addition to the Quantum Sniffer's quality and consistent performance, customers in Africa are choosing our systems due its low-maintenance design and non-contact sampling, which enables a low total cost of ownership," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones.

"We continue to expand our market share in Africa through our expanded sales force, our growing distribution network, and our increasing reputation of being the latest standard in explosives trace detection," added Glenn D. Bolduc, Implant Sciences' President and CEO.

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector

The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor Contact:
Laurel Moody
646-810-0608
Email Contact

$IMSC - Implant Sciences' Quantum Sniffers Play Growing Role in Corporate Security in Africa

WILMINGTON, MA -- (MARKETWIRE) -- 03/26/13 -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has sold its Quantum Sniffer™ QS-H150 handheld explosives trace detector to a customer in Africa for use in corporate security for a financial institution.

Some regions in Africa have experienced growing instability, with an increasing number of insurgencies and terrorist attacks, particularly on foreign interests. The response from security providers has been an increasing reliance on Quantum Sniffers to meet their security needs.

"Quantum Sniffers work consistently in difficult environments. In addition to the Quantum Sniffer's quality and consistent performance, customers in Africa are choosing our systems due its low-maintenance design and non-contact sampling, which enables a low total cost of ownership," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones.

"We continue to expand our market share in Africa through our expanded sales force, our growing distribution network, and our increasing reputation of being the latest standard in explosives trace detection," added Glenn D. Bolduc, Implant Sciences' President and CEO.

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector

The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor Contact:
Laurel Moody
646-810-0608
Email Contact

IMSC - Fox News Airs Segment on Implant Sciences' Quantum Sniffer Technology Nationwide

WILMINGTON, MA--(Marketwire - Mar 20, 2013) - Implant Sciences Corporation (OTCQB :IMSC), a high technology supplier of systems and sensors for homeland security markets, announced today the nationwide airing of a story featuring the Company by Fox News. The report, which aired Sunday, March 17, 2013, notes that Implant Sciences' Quantum Sniffer™ QS-B220 was recently approved by the Transportation Security Administration (TSA).

Implant Sciences' President and CEO, Glenn D. Bolduc, commented that, "X-ray and metal detection detect anomalies. They don't tell you if it's an explosive. The steel shank in your shoe is metal, which would be detected by a metal detector but doesn't necessarily tell you if it's an explosive. The advantage to explosives trace (detection) is we're telling you exactly what it is that you've detected."

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector

The TSA approved Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 has a greatly reduced total cost of ownership when compared to other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:


Implant Sciences Corporation
Company
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor
Laurel Moody
646-810-0608
Email Contact

$IMSC - Implant Sciences: Fox News Airs Segment on Implant Sciences' Quantum Sniffer Technology Nationwide

WILMINGTON, MA--(Marketwire - Mar 20, 2013) - Implant Sciences Corporation (OTCQB :IMSC), a high technology supplier of systems and sensors for homeland security markets, announced today the nationwide airing of a story featuring the Company by Fox News. The report, which aired Sunday, March 17, 2013, notes that Implant Sciences' Quantum Sniffer™ QS-B220 was recently approved by the Transportation Security Administration (TSA).

Implant Sciences' President and CEO, Glenn D. Bolduc, commented that, "X-ray and metal detection detect anomalies. They don't tell you if it's an explosive. The steel shank in your shoe is metal, which would be detected by a metal detector but doesn't necessarily tell you if it's an explosive. The advantage to explosives trace (detection) is we're telling you exactly what it is that you've detected."

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector

The TSA approved Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 has a greatly reduced total cost of ownership when compared to other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:


Implant Sciences Corporation
Company
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor
Laurel Moody
646-810-0608
Email Contact

$IMSC - Implant Sciences: Fox News Airs Segment on Implant Sciences' Quantum Sniffer Technology Nationwide

WILMINGTON, MA--(Marketwire - Mar 20, 2013) - Implant Sciences Corporation (OTCQB :IMSC), a high technology supplier of systems and sensors for homeland security markets, announced today the nationwide airing of a story featuring the Company by Fox News. The report, which aired Sunday, March 17, 2013, notes that Implant Sciences' Quantum Sniffer™ QS-B220 was recently approved by the Transportation Security Administration (TSA).

Implant Sciences' President and CEO, Glenn D. Bolduc, commented that, "X-ray and metal detection detect anomalies. They don't tell you if it's an explosive. The steel shank in your shoe is metal, which would be detected by a metal detector but doesn't necessarily tell you if it's an explosive. The advantage to explosives trace (detection) is we're telling you exactly what it is that you've detected."

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector

The TSA approved Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 has a greatly reduced total cost of ownership when compared to other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:


Implant Sciences Corporation
Company
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor
Laurel Moody
646-810-0608
Email Contact

Fox News Airs Segment on Implant Sciences' Quantum Sniffer Technology Nationwide

WILMINGTON, MA--(Marketwire - Mar 20, 2013) - Implant Sciences Corporation (OTCQB :IMSC), a high technology supplier of systems and sensors for homeland security markets, announced today the nationwide airing of a story featuring the Company by Fox News. The report, which aired Sunday, March 17, 2013, notes that Implant Sciences' Quantum Sniffer™ QS-B220 was recently approved by the Transportation Security Administration (TSA).

Implant Sciences' President and CEO, Glenn D. Bolduc, commented that, "X-ray and metal detection detect anomalies. They don't tell you if it's an explosive. The steel shank in your shoe is metal, which would be detected by a metal detector but doesn't necessarily tell you if it's an explosive. The advantage to explosives trace (detection) is we're telling you exactly what it is that you've detected."

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector

The TSA approved Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 has a greatly reduced total cost of ownership when compared to other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:


Implant Sciences Corporation
Company
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor
Laurel Moody
646-810-0608
Email Contact

$IMSC - Implant Sciences: Fox News Airs Segment on Implant Sciences' Quantum Sniffer Technology Nationwide

WILMINGTON, MA--(Marketwire - Mar 20, 2013) - Implant Sciences Corporation (OTCQB :IMSC), a high technology supplier of systems and sensors for homeland security markets, announced today the nationwide airing of a story featuring the Company by Fox News. The report, which aired Sunday, March 17, 2013, notes that Implant Sciences' Quantum Sniffer™ QS-B220 was recently approved by the Transportation Security Administration (TSA).

Implant Sciences' President and CEO, Glenn D. Bolduc, commented that, "X-ray and metal detection detect anomalies. They don't tell you if it's an explosive. The steel shank in your shoe is metal, which would be detected by a metal detector but doesn't necessarily tell you if it's an explosive. The advantage to explosives trace (detection) is we're telling you exactly what it is that you've detected."

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector

The TSA approved Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 has a greatly reduced total cost of ownership when compared to other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:


Implant Sciences Corporation
Company
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor
Laurel Moody
646-810-0608
Email Contact

CNN Breaking News: House Intelligence Chairman Mike Rogers: There is a "high probability" Syria used chemical weapons on opposition forces.

$IMSC - Implant Sciences compared to $CELG - Celgene:

http://m.seekingalpha.com/article/1283001

$IMSC - Implant Sciences compared to $CELG - Celgene:

http://m.seekingalpha.com/article/1283001

$IMSC - Implant Sciences compared to $CELG - Celgene:

http://m.seekingalpha.com/article/1283001

$IMSC - Implant Sciences Wins $585,000 Contract for QS-H150 Explosives Trace Detectors to U.S. Government Agency

WILMINGTON, MA--(Marketwire - Mar 14, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has won a contract valued at approximately $585,000 for the sale of its Quantum Sniffer™ QS-H150 explosives trace detectors to a U.S. Government agency.

"Implant Sciences' products are capable of fulfilling counter-terrorism needs in a wide range of environments," noted Todd Swearingen, General Manager of the Americas for Implant Sciences. "The Company has recently received orders from a number of new U.S. Government customers, and we look forward to more in the coming months as our reputation for reliability, low total cost of ownership, ease of use, and precise detection continues to grow."

Darryl Jones, Implant Sciences' Vice President of Sales and Marketing, commented, "Our investment in sales and marketing infrastructure to serve the U.S. Government market is paying off, and we are now bidding for and winning contracts with U.S. Government agencies. The performance of our products under field conditions continues to open new opportunities with government decision makers. The recent TSA approval of the QS-B220 should only increase these opportunities."

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector
The TSA approved Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector
The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

http://m.yahoo.com/w/legobpengine/finance/news/implant-sciences-wins-585-000-130356590.html?.intl=us&.lang=en-us

$IMSC - Implant Sciences Wins $585,000 Contract for QS-H150 Explosives Trace Detectors to U.S. Government Agency

WILMINGTON, MA--(Marketwire - Mar 14, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has won a contract valued at approximately $585,000 for the sale of its Quantum Sniffer™ QS-H150 explosives trace detectors to a U.S. Government agency.

"Implant Sciences' products are capable of fulfilling counter-terrorism needs in a wide range of environments," noted Todd Swearingen, General Manager of the Americas for Implant Sciences. "The Company has recently received orders from a number of new U.S. Government customers, and we look forward to more in the coming months as our reputation for reliability, low total cost of ownership, ease of use, and precise detection continues to grow."

Darryl Jones, Implant Sciences' Vice President of Sales and Marketing, commented, "Our investment in sales and marketing infrastructure to serve the U.S. Government market is paying off, and we are now bidding for and winning contracts with U.S. Government agencies. The performance of our products under field conditions continues to open new opportunities with government decision makers. The recent TSA approval of the QS-B220 should only increase these opportunities."

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector
The TSA approved Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector
The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

http://m.yahoo.com/w/legobpengine/finance/news/implant-sciences-wins-585-000-130356590.html?.intl=us&.lang=en-us

$IMSC - Implant Sciences Wins $585,000 Contract for QS-H150 Explosives Trace Detectors to U.S. Government Agency

WILMINGTON, MA--(Marketwire - Mar 14, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has won a contract valued at approximately $585,000 for the sale of its Quantum Sniffer™ QS-H150 explosives trace detectors to a U.S. Government agency.

"Implant Sciences' products are capable of fulfilling counter-terrorism needs in a wide range of environments," noted Todd Swearingen, General Manager of the Americas for Implant Sciences. "The Company has recently received orders from a number of new U.S. Government customers, and we look forward to more in the coming months as our reputation for reliability, low total cost of ownership, ease of use, and precise detection continues to grow."

Darryl Jones, Implant Sciences' Vice President of Sales and Marketing, commented, "Our investment in sales and marketing infrastructure to serve the U.S. Government market is paying off, and we are now bidding for and winning contracts with U.S. Government agencies. The performance of our products under field conditions continues to open new opportunities with government decision makers. The recent TSA approval of the QS-B220 should only increase these opportunities."

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector
The TSA approved Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector
The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

http://m.yahoo.com/w/legobpengine/finance/news/implant-sciences-wins-585-000-130356590.html?.intl=us&.lang=en-us

$IMSC - Implant Sciences featured in Government Security News February, 2013 issue:

http://www.implantsciences.com/pdf/GSN20130201.pdf

$IMSC - Implant Sciences featured in Government Security News February, 2013 issue:

http://www.implantsciences.com/pdf/GSN20130201.pdf

$IMSC - Implant Sciences featured in Government Security News February, 2013 issue:

http://www.implantsciences.com/pdf/GSN20130201.pdf